

Chemistry Updates*

February 2025

*Subject to change. Refer back to this page regularly for updates.

Major changes

Phased go-live

New assays/orderables:

◆Hs-cTnI to hs-cTnT
◆BNP to NT-proBNP
◆Three additional tests in the Drug of Abuse (DAU) panel
◆Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

Ammonia, hsTnT and NT-proBNP: tube type change
 ◆DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)

Reference range, unit and calculation changes

Discontinued/sendout

Discontinued testsTemporary send out

Hemolysis reporting

Big picture

- Changing the major chemistry automation system from Siemens to Roche
- Old Siemens instruments are breaking (urgency to switch)
- Standardization with other NYP hospitals

Project Timelines

Project	Status	February	March	April	Мау	June	July
Roche Cobas Pro Phase 1 Payson 8	In Progress	Go-Live N	Narch 11				
Roche Cobas Pro Phase 2 Payson 8	In Progress	Tentativ	e Go-Live Apr	il/May			
Roche Automation Phase 3 Payson8	Planning		Т	entative Go-L	.ive June/Jul	у	
Roche Pure Phase 4 DHK	Planning		T	entative Go-L	.ive June/Jul	у	

Phase 1: critical/priority test menu

March 11, 2025


Acataminanhan Laval	Chalastaral I DI Direct	Hapatitic A. P. C. Drofila	Phosphorus Level
Acetaminophen Level	Cholesterol LDL Direct	Hepatitis A B C Profile	· ·
Acute Hepatitis Panel	CMP	Hepatitis B Core Ab	Phosphorus Level Urine Random
Adrenal Vein Sampling (Cort LAV/Cort IVC)	Cortisol	Hepatitis B Core Antibody IgM	Potassium Level
Albumin Level	Creatine Kinase	Hepatitis B Surface Antibody	Potassium Level Urine Random
Albumin Level Urine Random	Creatinine	Hepatitis B Surface Antigen	Procalcitonin
Alkaline Phosphatase	Creatinine Urine Random	Heptatitis A B Profile	Protein CSF
ALT	CRP (Inflammation)	Heptatitis B Profile	Protein Total
		HIV 1 and 2 Maternal-Newborn Screen 4th	
Amikacin Level	Digoxin Level	Generation	Protein Urine Random
		HIV 1 and 2 Occupational Exposure 4th	
Ammonia Level	Electrolyte Panel	Generation	PTH Intact
Amylase Level	Electrolyte Panel Urine Random	HIV 1 and 2 Rapid 4th Generation	PTH Interoperative Base
Amylase Level Urine Random	Ethanol Level	HIV 1/2/P24 Combo	PTH Interoperative Post
AST	Ferritin	Insulin	Renal Function Panel
Beta Hydroxybutyric Acid	Folate Serum	Iron	Salicylate Level
Beta-HCG Quantitative	Free T4	IronTIBC	Sodium Level
Bilirubin Direct	Gentamicin Level	Lactate Dehydrogenase	Sodium Level Urine Random
Bilirubin Total	Glucose CSF	Lactic Acid	Tobramycin Level
ВМР	Glucose Plasma	Lactic Acid CSF	Troponin T, High Sensitivity
Bun/ Creat Ratio	Glucose Random	Lipase Level	тѕн
Calcium Level Total	Glucose Urine Random	Lipid	TSH w/r FT4
Calcium Urine Random	Haptoglobin	Lithium Level	Urea Nitrogen Urine
Carbamazepine Level	Hep Bs Ag Mat	Magnesium Level	Uric Acid
	Hep C Ab Total w/refl to HCV RNA		
Carbon Dioxide Level	NAAT	Magnesium Level Urine	Urine Prot/Creat Ratio
Cardiac CRP	Hepatic	NT-proBeta-Natriuretic Peptide	Valproic Acid Level
Chloride Level	Hepatitis A Antibody	Phenobarbital Level	Vancomycin Level
Chloride Level Urine Random	Hepatitis A Antibody IgM	Phenytoin Level Total	Vitamin B12 Level

Phase 2: test menu

April/May, 2025

Albumin Level Body Fluid	IgE	
Alpha Fetoprotein Tumor Marker	Lactate Dehydrogenase Body Fluid	
Amylase Level Body Fluid	LDH CSF (LDT)	
Anti-Nucleocapsid (N) SARS-CoV-2 Ab	Lipase Level Body Fluid	
Anti-S SARS-CoV-2 Ab	Luteinizing Hormone	
ASO	Methotrexate Level	
Bilirubin Body Fluid	Potassium Level Body Fluid	
C3 Complement	Progesterone Level	
C4 Complement	Prolactin Level	
CA 125	Prostate Specific Antigen	
CA19-9	Protein Body Fluid	
Cancer Antigen 15-3	Rheumatoid Factor Quantitative	
Carcinoembryonic Antigen	Sodium Level Body Fluid	
Carcinoembryonic Antigen Body Fluid	Τ4	
Chloride Level Body Fluid (LDT)	Testosterone Level Total	
Cholesterol Body Fluid	Theophylline Level	
Creatinine Body Fluid	Toxoplasma IgG	
Drugs of Abuse Urine No Confirmation	Toxoplasma IgM	
Estradiol Level	Triglyceride Body Fluid	
FSH	Triiodothyronine	
Gamma Glutamyl Transferase	Urea Nitrogen Body Fluid	
Glucose Body Fluid		
Gonadotropin Panel		
Homocysteine		

Phase 3: full automation (June, 2025)



Phase 4: DHK lab


(Go Live Target: June-July, 2025)

Future Test Menu:

- CMP
- BMP

•

- Hepatic Panel
- Magnesium
- Phosphorus



Turnaround time will be monitored and optimization will be made when available.

Major changes

• Phased go-live

- New assays/orderables:
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures


- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

hs-Troponin I \rightarrow hs-Troponin T


What will be the changes for Troponin

- Clinical pathway for ACS and Troponin Algorithm
- Result interpretation
- Sample type
- Sample collection
- Interference (hemolysis→ falsely low)
- Pathophysiological factors impacting Troponin

Cardiac Troponin




Cardiac vs Skeletal Troponins TnT and TnI



Troponins T and I have unique cardiac isoforms, whereas cardiac and skeletal muscle share troponin C isoforms.

https://www.degruyter.com/downloadpdf/j/dx.2019.6.i ssue-3/dx-2019-0045/dx-2019-0045.pdf



Usage Principles

This algorithm does not replace clinical judgement. Clinical context varies and this algorithm can not be interpreted as defining standard of care for all cases. E.g., not all patients with chest pain require lab testing to rule out a Myocardial Infarction (MI).

This algorithm is intended for the initial evaluation of a patient presenting with symptoms concerning for possible ACS (including Type 1 and 2 MI). For those patients in the red or yellow endpoint, once admitted, further risk stratification based on pre-test probability, additional testing where indicated, anticipated follow-up, and other factors is appropriate.

Other conditions besides ACS can cause an elevation in troponin (see appendix). Hemolysis or biotin usage may cause falsely low measurement of hs-TnT

Definitions and Timing h0 = Time of initial troponin test h1 = One hour after h0 h3 = Three hours after h0

Δhs-TnT = change from h0 (either rise or fall may be significant)

If the second troponin is drawn >= 3 hours after the first, interpret as if a h3 troponin.

If the patient is being admitted for other reasons, admission does not necessarily need to be delayed for to wait for h1 and h3 troponin.

Notes

A. Use clinical context (e.g. history, exam, and ECG) to risk stratify decision to use care pathway. If there is a high suspicion for ACS (e.g. acute ischemic changes on ECG or story highly concerning) then cannot rule out MI via this pathway. Serial Troponin testing as per the pathway is still relevant however as it can help with risk stratification to guide further management.

B. Exercise clinical judgement in cases of chronic, stable elevated troponin (e.g. some patients with CKD)

C. LRs from Allen BR, Christenson RH, Cohen SA, et al. Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort. Circulation. 2021;143(17):1659-1672.

D. NOTE: If h1 troponin drawn "late" (near or after 2 hours) and Δ hs-TnT 5-9 ng/L, consider retesting h3 instead of proceeding to red path


E. No early evidence of myocardial infarction by biomarkers, consider other causes of symptoms. Most patients can be discharged unless high suspicion of ACS (e.g. acute ischemic changes on ECG or story highly concerning) or other there are non-ACS diagnoses of concern.

F. Alternate plans can be considered in select patients with shared decision making. Be certain to consider non-ACS causes of troponin rise (see appendix).

Hs-cTnT and hs-cTnI do not correlate!

	NEW	OLD	
	hs-Trop- <mark>T</mark>	hs-Trop-l	
Reference Range	Female: ≤14 ng/L Male: ≤22 ng/L	Female: ≤40 ng/L Male: ≤58 ng/L	
Abnormal Value	Female: 15-51 ng/L Male: 23-51 ng/L <i>Marked Red</i>	Female: 41-199 ng/L Male: 59-199 ng/L <i>Marked Red</i>	
Critical Value	≥52 ng/L Notification Required	≥200 ng/L Notification Required	

Roche hs-cTnT



Collecting hs-Trop-T

for Nurses



Specimen Collection (2)	on/Tasks 😞
Overdue (1)	
🗹 Due in next 60 min	(1)
Labs - Unit Print Label for TROPONIN-T, HIGH SENSITIVITY 0 HOUR	▶ 0938
Print Label for TROPONIN-T, HIGH SENSITIVITY 1 HOUR	1038

Collect the 0 Hour Troponin first.

- It is important to collect the first hs-Trop-T specimen (0 Hour) before collecting the second one (1 Hour).
- The first hs-Trop-T specimen (0 Hour) is indicated in red with the earliest time (1).
- The second hs-Trop-T specimen (1 Hour) is indicated in **black** 1 hour later (2).
- If you accidentally collect the second specimen first, you will NOT receive a notification to collect the second hs-Trop-T.

Collecting hs-Trop-T

for Nurses

Printing the 1 hour hs-Trop-T too early:

STOP! Do not use this label on tube hsTNT 1HR LABEL PRINTED TOO SOON! Wait at least 55 min after collecting hsTNT 0HR before printing this label Error printed at: 8/21/2023 13:09

Printing the 3 hour hs-Trop-T too early:

STOP! Do not use this label on tube hsTNT 3HR LABEL PRINTED TOO SOON! Wait at least 2 hrs after collecting hsTNT OHR before printing this label Error printed at: @TD@ @NOW(1)@


Don't collect specimens too late <u>or too early</u>.

Wait at least 55 minutes to collect the 1 Hour hs-Trop-T after collecting the 0 Hour hs-Trop-T. Otherwise you will see a lockout print label.

Wait at least 2-3 hours to collect the 3 Hour hs-Trop-T after collecting the 0 Hour hs-Trop-T. Otherwise you will see a lockout print label.

Collecting hs-Trop-T

for Nurses



A Rover alert will remind you when to collect the 1 Hour Troponin.

This Rover alert will fire **55 minutes** after the 0 Hour hs-Trop-T is collected.

For the alert to fire appropriately, you MUST accurately document the collection time (not the label printing time) of the 0 Hour hs-Trop-T.

for Providers

Default Orders if the Patient has No Troponins Yet

rapanin (R/O MI)	
Which type of troponin testing does this patient need?	
0 Hour + 1 Hour Serial Troponins	
TROPONIN-T, HIGH SENSITIVITY 0 HOUR Once, today at 1655, For 1 occurrence Release to patient: Immediate	- Remove
ca And	
TROPONIN-T, HIGH SENSITIVITY 1 HOUR Once timed, today at 1755, For 1 occurrence Release to patient: Immediate	- Remove
Release to patient: Immediate O Add-On 3 Hour Troponin (after 0 Hour Troponin was already sent)	
 Add-On 3 Hour Troponin (after 0 Hour Troponin was already sent) Repeat Troponin for Hemolyzed Specimen 	

Always use the Troponin (R/O MI) Order Panel.


The appropriate orders will be defaulted based on the patient's troponin history.

If the patient has no troponins ordered yet, the 0 Hour and 1 Hour tests will be defaulted.

If the patient's last troponin test was hemolyzed, the "repeat troponin for hemolyzed specimen" option will be defaulted.

for Providers

Alert When Opening a Duplicate 0 Hour Troponin Order



Alert When Signing a Duplicate 0 Hour Troponin Order

Or You cannot sign these orders because information is missing or requires your attention: This patient already has an active 0 Hour Troponin order placed within the past 8 hours. If this patient needs a repeat


troponin, place a 3 Hour Troponin order or random troponin order

₿ QK Avoid duplicate 0 Hour Troponin orders less than 8 hours apart.

The system cannot calculate the difference between serial troponins if there are duplicate 0 Hour Troponin orders placed too closely together.

You will see these alerts if you attempt to order a duplicate 0 Hour Troponin.

for Providers



Always use the Troponin (R/O MI) Order Panel.

If you are adding a 3 Hour troponin based on the results of the 0 Hour troponin, click on the "add-on 3 hour" option.

The collection time of the 0 Hour troponin will be displayed, with instructions on how to enter the frequency for the 3 Hour troponin order.

Interpreting hs-Trop-T

for Providers

What if the sample was drawn outside the 1 hour or 3 hour window?


If the **second** hs-Trop-T was drawn **1-3 hours** after the **first** hs-Trop-T

> Interpret as if it were a **1 Hour hs-Trop-T**

If the **second or third** hs-Trop-T was drawn **more than 3 hours** after the **first** hs-Trop-T

> Interpret as if it were a 3 Hour hs-Trop-T

Hemolysis may cause falsely low Roche Hs-cTnT



Clin Chem, Volume 56, Issue 8, 1 August 2010, Pages 1357–1359, https://doi.org/10.1373/clinchem.2010.144139. T

for Providers

nich type of troponin testing does this patient ne	ed?
Hour + 1 Hour Serial Troponins	
dd-On 3 Hour Troponin (after 0 Hour Troponin	was already sent)
Repeat Troponin for Hemolyzed Specimen	
If 0 Hour was Hemolyzed	
If 1 Hour was Hemolyzed	
O If 3 Hour was Hemolyzed	

Always use the Troponin (R/O MI) Order Panel.

If the patient's last troponin was hemolyzed, the "repeat troponin for hemolyzed specimen" option will be defaulted in the order panel. Select which sample was hemolyzed to automatically get the correct orders.

✓ Accept Troponin (R/O MI) Which type of troponin testing does this patient need? O Hour + 1 Hour Serial Troponins O Add-On 3 Hour Troponin (after 0 Hour Troponin was already sent) Repeat Troponin for Hemolyzed Specimen If 0 Hour was Hemolyzed Cancel any 1 Hour or 3 Hour Troponin that was previously ordered. Re-order the 0 Hour + 1 Hour Serial Troponins below. O Hour + 1 Hour Serial Troponins TROPONIN-T, HIGH SENSITIVITY 0 HOUR Once, today at 1657, For 1 occurrence Release to patient: Immediate TROPONIN-T, HIGH SENSITIVITY 1 HOUR Once timed, today at 1757, For 1 occurrence Release to patient: Immediate O If 1 Hour was Hemolyzed If 3 Hour was Hemolyzed Next Required Accept

for Providers

Always use the Troponin (R/O MI) Order Panel.

If you indicate that the **0 Hour troponin was hemolyzed**, you will be instructed to:

- Cancel any 1 Hour or 3 Hour troponin that was previously ordered
- Reorder the 0 Hour + 1 Hour serial troponins (these will be defaulted).

Troponin (R/O MI) ✓ Accept Which type of troponin testing does this patient need? O Hour + 1 Hour Serial Troponins O Add-On 3 Hour Troponin (after 0 Hour Troponin was already sent) Repeat Troponin for Hemolyzed Specimen If 0 Hour was Hemolyzed If 1 Hour was Hemolyzed Order a 3 Hour Troponin below (to receive a 3 Hour Delta calculation automatically) and/or a new random Troponin below (to calculate the Delta manually). TROPONIN-T, HIGH SENSITIVITY 3 HOUR Once TROPONIN-T, HIGH SENSITIVITY Once If 3 Hour was Hemolyzed Next Required ✓ Accept

for Providers

Always use the Troponin (R/O MI) Order Panel.

If you indicate that the **1 Hour troponin was hemolyzed**, you will be instructed to:

 Order a 3 Hour troponin (to receive a delta calculation automatically)

AND/OR

 Order a new random troponin (to calculate the delta manually)

Troponin (R/O MI) ✓ Accept Which type of troponin testing does this patient need? 0 Hour + 1 Hour Serial Troponins O Hour + 1 Hour Serial Troponin (after 0 Hour Troponin was already sent) ● ● Repeat Troponin for Hemolyzed Specimen ● If 0 Hour was Hemolyzed ● If 1 Hour was Hemolyzed ● Order a new random Troponin below. You will need to calculate the Delta manually. ✓ TROPONIN-T, HIGH SENSITIVITY Once, today at 1657, For 1 occurrence Release to patient: Immediate Blood Blood

for Providers

Always use the Troponin (R/O MI) Order Panel.

If you indicate that the **3 Hour troponin was hemolyzed**, you will be instructed to:

 Order a new random troponin (you will need to calculate the delta manually).

✓ Accept

<u>O Hour</u> Troponin (No Hemolysis)

ort Viewer							7
		-	and a state of the state of the				Ŷ
eport History 1 View pane 1 2 View		Det Det Det Det Det	ach Window				
day at 09.51 TROPONIN-T, HIGH SE	INSITIVITY I HOUR						
TROPONIN-T, HIGH SENSIT	IVITY O HOUR				Status:	Final result Connect:	Pt Inactiv
	11-1-1						
Troponin T HS 0 Hour	Value 10			Range			
Comments:	10			<=22 ng	y/c		
Serial high sensitivity t		within the normal we		he alinias	11	and if papart la	
rapidly increasing. Spec							
	carroarth, a cusude r						
	the initial test may h				rand werden and	several several	
the first 3 hours after t					tion.		
					ation.		
the first 3 hours after t	always be used in con	junction with the pa	tient's clinic	al presenta		at least 8 hours a	after
the first 3 hours after t troponin results should a	always be used in con ken from patients rec	junction with the pa	tient's clinic	al presenta		at least 8 hours a	after
the first 3 hours after t troponin results should a Samples should not be tab	always be used in con ken from patients rec	junction with the pa	tient's clinic	al presenta		at least 8 hours :	after
the first 3 hours after t troponin results should a Samples should not be tab	always be used in con ken from patients rec	junction with the pa	tient's clinic	al presenta		at least 8 hours (after
the first 3 hours after t troponin results should a Samples should not be ta) the last biotin administr	always be used in con ken from patients rec	junction with the pa eiving therapy with CL	tient's clinic high biotin do	al presenta ses (> 5mg/	/day) until a		after
the first 3 hours after to troponin results should a Samples should not be tab the last biotin administr Performing Lab; NYP_Columbia Director: HOD, M.D., ELDAD A.	always be used in con ken from patients rec	junction with the pa eiving therapy with CL	tient's clinic high biotin do: NA: 33D0664187 Idress: 622 West	al presenta ses (> 5mg/	/day) until (New York NY 10		

<u>1 Hour</u> Troponin with Delta (No Hemolysis)

SnapShot Chart Review R	eview Flowsheets Result	s Report	Synopsis History	Allergies	Problems	Medications	Immunizations	Demographics	
rt Viewer eport History] View pane 2 🔤 Split U	olDown 頂 S	Split Left/Right 🗗 D	etach Wind	3ow				٢
day at 10:50 TROPONIN-T, HIGH C 品 色 唱 唱	SENSITIVITY 1 HOUR	Abnormal							
TROPONIN-T, HIGH S	ENSITIVITY 1 HOU	R					Status:	Final result Connect:	Pt Inactiv
roponin T HS 1 Hour		Value 30 (H)				Range <=22 n	g/L		
Comments: Serial high sensitivit rapidly increasing. S the first 3 hours afte troponin results shoul Samples should not be the last biotin admini	pecifically, a cha r the initial test d always be used i taken from patient	nge in hi may be i n conjunc	gh sensitivity ndicative of my tion with the p	troponi yocardia patient'	n level 1 injury 8 clinic	of >= 3 ng, . Nonethele al presente	/L in the fir ess, high ser ation.	rst hour or >= 6n haitivity cardiac	g/L over
Hr Delta hsTNT		20 (H)				<=2 ng	/L		
Performing Lab: NYP_Columb	ia		3	CLIA: 33D	0664187				
Director: HOD, M.D., ELDAD A			4	Address:	622 West	168th Street	New York NY 10	032	
Accession #: 22323440003	Specimen Type: Blood		Specimen Collected	1: 08/22/23	3			pecimen Received Dat 8/22/23 3:21 PM	te:
ast Resulted: 08/22/23 3:32 PM									

<u>3 Hour</u> Troponin (No Hemolysis)

SnapShot Chart Review Review Flow	sheets Results Report Syn	opsis History Allergies	Problems Medications	Immunizations Demographic	s •	\$
port Viewer					02	>
Report History View pane 1 2 View pan	e 2 📰 Split Up/Down 🕕 Split	Left/Right	dow			
Today at 12:50 TROPONIN-T, HIGH SENSITI	VITY 3 HOUR Abnormal					_
· C H O B B						s
TROPONIN-T, HIGH SENSITI	VITY 3 HOUR			Status: Final result Co	nnect: Pt Inactive	^
	Value		Range			
Troponin T HS 3 Hour	60 (AA)		<=22 n	g/L		
Comments: Critical result(s) called by	RE date/time 8/22/2023	15:34:33 EDT.				
Information received and read						
Serial high sensitivity tropo rapidly increasing. Specific the first 3 hours after the i troponin results should alway	ally, a change in high nitial test may be ind	sensitivity tropon cative of myocardi	in level of >= 3 ng. al injury. Nonethel	L in the first hour or ess, high sensitivity ca	>= 6ng/L over	
Samples should not be taken f the last biotin administratio		therapy with high !	biotin doses (> Smg.	(day) until at least 8 h	ours after	
3Hr Delta hsTNT	50 (H)		<=5 ng	/L		
Performing Lab: NYP_Columbia		CLIA: 330	0664187			
Director: HOD, M.D., ELDAD A.		Address:	622 West 168th Street	New York NY 10032		
Accession #: 22323440004 Specim		cimen Collected: 08/22/2 50 pm	3	Specimen Receiv	2010-0-0-1	~

Hemolyzed with Abnormal Value in Comment

-> SnapShot Chart Review Rev	iew Flowsheets R	esults Report	Synopsis History	Allergies	Problems	Medications	Immunizations	Demographics	•	
port Viewer									© 2	
Report History View pane 1 2 Today at 15.40 TROPONIN-T, HIGH 1		11.2.4.12.9.1 MIX 12.1	Split Left/Right 🕞 (Detach Win	iow					_
- C A + C -										
TROPONIN-T, HIGH SE	NSITIVITY						Status:	Final result Connect:	Pt Inactive	
		Value				Range				
Troponin-T, High Sensitivity		Hemoly	zed, See note (A)			<=22 n	g/L			
Comments:										
Result is 35 ng/L. CAUT is unreliable for thera							cantly lower	than the true va	lue, It	
Serial high sensitivity rapidly increasing. Sp										
the first 3 hours after		Strate and the second		10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						
troponin results should									8	
Samples should not be t the last biotin adminis		ents receiv	ving therapy wit	h high b	iotin do	ses (> 5mg.	/day) until (at least 8 hours	after	
the last blotin adminis	cration.									
Performing Lab: NYP_Columbia				CLIA: 33D	0664187					
Director: HOD, M.D., ELDAD A.				Address:	622 West	168th Street	New York NY 10	032		
Accession #: 22323440026	Specimen Type: B	lood	Specimen Collecte 3:40 PM	d: 08/22/2	3			Specimen Received Dat 08/22/23 3:40 PM	te:	
Last Resulted: 08/22/23 3:40 PM										

Hemolyzed with Critical Value in Comment

ort Viewer				(?)
A CONTRACTOR OF A CONTRACTOR O				0
eport History 🚺 View pane 1 🕃 View pane 2 📰 Spl		iow		
day at 15:41 TROPONIN-T, HIGH SENSITIVITY Abnor	mal			
	Value	Range		
Troponin-T, High Sensitivity	Hemolyzed, Critical (AA)	<=22 ng	a/L	
Comments:				
Critical result(a) called by BE date/	time 8/22/2023 15:42:27 EDT.			
errered repart(s) carres by an ances				
		his result is inacc	urate due to hemolysis and	may be
Information received and read back by	JS. Result is 61 ng/L. CAUTION! T			the second s
Information received and read back by significantly lower than the true values	JS. Result is 61 ng/L. CAUTION! T			Contraction of the second s
Information received and read back by	JS. Result is 61 ng/L. CAUTION! T			Contraction of the second s
Information received and read back by significantly lower than the true valu advised.	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut	ic decisions. Testi	ng of a new sample is stron	ngly
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measu	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut urements within the normal range m	ic decisions. Testi ay still be clinica	ng of a new sample is stron	ngly Levels are
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measu rapidly increasing. Specifically, a compared to the sense of t	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi	ic decisions. Testi ay still be clinics n level of >= 3 ng/	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6	ngly Levels are éng/L over
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a d the first 3 hours after the initial to	JS. Result is 61 ng/L) CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 as, high sensitivity cardia	ngly Levels are éng/L over
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measu rapidly increasing. Specifically, a compared to the sense of t	JS. Result is 61 ng/L) CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 as, high sensitivity cardia	ngly Levels are éng/L over
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a of the first 3 hours after the initial to troponin results should always be used	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient'	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele s clinical presents	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation.	ngly levels are éng/L over ac
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a d the first 3 hours after the initial to troponin results should always be used Samples should not be taken from pation	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient'	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele s clinical presents	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation.	ngly levels are éng/L over ac
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a of the first 3 hours after the initial to troponin results should always be used	JS. Result is 61 ng/L. CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient'	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele s clinical presents	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation.	ngly levels are éng/L over ac
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a d the first 3 hours after the initial te troponin results should always be used Samples should not be taken from patient the last biotin administration.	JS. Result is 61 ng/L) CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient' ents receiving therapy with high b	ic decisions. Testi ay still be clinics n level of >= 3 ng/ l injury. Nonethele s clinical presents iotin doses (> 5mg/	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation.	ngly levels are éng/L over ac
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measu rapidly increasing. Specifically, a of the first 3 hours after the initial to troponin results should always be used Samples should not be taken from patient the last biotin administration. Performing Lab: NYP_Columbia	JS. Result is 61 ng/L) CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient' ents receiving therapy with high b CLUA: 33D	ic decisions. Testi ay still be clinica n level of >= 3 ng/ l injury. Nonethele s clinical presents iotin doses (> 5mg/ 0664187	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation. day) until at least 8 hours	ngly levels are éng/L over ac
Information received and read back by significantly lower than the true valu advised. Serial high sensitivity troponin measurapidly increasing. Specifically, a d the first 3 hours after the initial te troponin results should always be used Samples should not be taken from patient the last biotin administration.	JS. Result is 61 ng/L) CAUTION! T ue. It is unreliable for therapeut urements within the normal range m change in high sensitivity troponi est may be indicative of myocardia d in conjunction with the patient' ents receiving therapy with high b CLIA: 33D0 Address:	ic decisions. Testi ay still be clinica n level of >= 3 ng/ l injury. Nonethele s clinical presenta lotin doses (> 5mg/ 0664187 622 West 168th Street ()	ng of a new sample is stron ally significant if repeat 1 L in the first hour or >= 6 ass, high sensitivity cardia ation. day) until at least 8 hours	ngly levels are ing/L over ac s after

Pathophysiological factors impacting Troponin

•cTnT is more affected by renal dysfunction


•Skeletal muscle disease (e.g., myopathy) can cause troponin elevations, especially cTnT, due to skeletal muscle expression.

•cTnI is more susceptible to macrotroponin (complexes of cardiac troponin with other proteins in the blood) interference but less influenced by CKD.

hs-Troponin T: Key Resources

- NYP Clinical Pathway for ACS and the Evaluation of Chest Pain
- <u>hs-Troponin-T Algorithm</u>
- <u>https://knowit.nyp.org/Inpatient_Nursing_and_Clinical_Roles/Troponin.htm?rhsearch=troponin&rhhlterm</u> <u>=troponin</u>
- <u>https://knowit.nyp.org/Clinical_Roles/High_Sensitivity_Troponin.htm?rhsearch=troponin&rhhlterm=tropon</u> <u>in%20troponins</u>

$BNP \rightarrow NT$ -proBNP



- NT-proBNP and BNP are products of a single precursor proBNP.
- The 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure recommends testing with either assay to establish presence and severity of heart failure.

BNP → NT-proBNP Do not correlate!

Old: BNP

Stability

24 hours - room temperature24 hours - refrigerated9 months - frozen

Specimen type Plasma (Lav EDTA)

Reference range ≤100 pg/mL

New: NT-proBNP

Stability

3 days - room temperature6 days - refrigerated24 months - frozen

Specimen type Serum (SST)

Reference range 0 to 75 years old: ≤ 124 pg/mL > 75 years old: ≤ 449 pg/mL

Three additional tests in the DAU panel


- Current DAU panel: opiate, oxycodone, amphetamine, barbiturates, benzodiazepine, cocaine, fentanyl, methadone, Marijuana, PCP (with specimen validity testing: pH, creatinine, specific gravity, oxidants).
- We will add 3 tests to the DAU panel:
- *** 6-acetylmorphine** (heroin metabolite)
- ✤ buprenorphine
- hydrocodone
- In addition, we will test EDDP (methadone metabolite) instead of methadone to monitor methadone compliance.

Iron & TIBC→ Iron & TIBC with Transferrin Saturation

Current on								
Siemens	IRON + TIBC			Status: Final result Conn	ect: Released on 2/2/2025 2:52 PM			
		Val		Range				
	Iron Level	30	(L)	50 - 170 ug/dL				
Measured —	TIBC Direct	27	0	250 - 425 ug/dL				
	Iron Saturation		1.1 (L) 13.0 - 53.0 %					
	Performing Lab: NYP_Corne		CLIA: 33D					
	Director: CUSHING, M.D.,M	ELISSA	Address:	525 East 68th Street New York N	IY 10065			
	Accession #: 12503302195	Specimen Type: Blood	Specimen Collected: 02/02/ 7:36 AM	25	Specimen Received Date: 02/02/25 9:12 AM			
	Last Resulted: 02/02/25 2:52 PM							
	⊞ව∿§⊮ຊ໑							

New on Roche	IRON & TIBC V	WITH TRANSFERRI	N SATURATION	Status: Final I	result Connect: Pt Inactive					
	O Newer results are available. Click to view them now.									
Calavilated	Iron Level	Value		Range 61 - 157 ug/d	L					
Calculated	Iron Binding Capacity	Total 183		171 - 505 ug/dL						
Measured 💳	UIBC	171		a/dL						
Ivicasurca	Transferrin Saturation	(TSAT) (CAT)	20 - 50 %							
	Performing Lab: NY	P_Cornell	CLIA: 33D	0653378						
	Director: CUSHING,	M.D., MELISSA	Address:	525 East 68th Street	New York NY 10065					
	Accession #: 12503140029	Specimen Type: Blood	Specimen Collected: 01/31/25 7:13 AM		Specimen Received Date: 01/31/25 3:13 PM					
	Last Resulted: 01/31/25 5:00 PM	5								
	≣୭୬≹ଏ	¤ , 9								

$BNP \rightarrow NT$ -proBNP



- NT-proBNP and BNP are products of a single precursor proBNP.
- The 2022 AHA/ACC/HFSA Guideline for Management of Heart Failure recommends testing with either assay to establish presence and severity of heart failure.

BNP → NT-proBNP Do not correlate!

Old: BNP

Stability

24 hours - room temperature24 hours - refrigerated9 months - frozen

Specimen type Plasma (Lav EDTA)

Reference range ≤100 pg/mL

New: NT-proBNP

Stability

3 days - room temperature6 days - refrigerated24 months - frozen

Specimen type Serum (SST)

Reference range 0 to 75 years old: ≤ 124 pg/mL > 75 years old: ≤ 449 pg/mL

BNP \rightarrow NT-proBNP: specimen type

Do not correlate!



Three additional tests in the DAU panel

- Current DAU panel: opiate, oxycodone, amphetamine, barbiturates, benzodiazepine, cocaine, fentanyl, methadone, Marijuana, PCP (with specimen validity testing: pH, creatinine, specific gravity, oxidants).
- We will add 3 tests to the DAU panel: 6-acetylmorphine (heroin metabolite), buprenorphine and hydrocodone. In addition, we will test EDDP (methadone metabolite) instead of methadone to monitor methadone compliance.

Iron & TIBC→ Iron & TIBC with Transferrin Saturation

Current on								
Siemens	IRON + TIBC			Status: Final result Conn	ect: Released on 2/2/2025 2:52 PM			
		Val		Range				
	Iron Level	30	(L)	50 - 170 ug/dL				
Measured —	TIBC Direct	27	0	250 - 425 ug/dL				
	Iron Saturation		1.1 (L) 13.0 - 53.0 %					
	Performing Lab: NYP_Corne		CLIA: 33D					
	Director: CUSHING, M.D.,M	ELISSA	Address:	525 East 68th Street New York N	IY 10065			
	Accession #: 12503302195	Specimen Type: Blood	Specimen Collected: 02/02/ 7:36 AM	25	Specimen Received Date: 02/02/25 9:12 AM			
	Last Resulted: 02/02/25 2:52 PM							
	⊞ව∿§⊮ຊ໑							

New on Roche	IRON & TIBC V	WITH TRANSFERRI	N SATURATION	Status: Final I	result Connect: Pt Inactive					
	O Newer results are available. Click to view them now.									
Calavilated	Iron Level	Value		Range 61 - 157 ug/d	L					
Calculated	Iron Binding Capacity	Total 183		171 - 505 ug/dL						
Measured 💳	UIBC	171		a/dL						
Ivicasurca	Transferrin Saturation	(TSAT) (CAT)	20 - 50 %							
	Performing Lab: NY	P_Cornell	CLIA: 33D	0653378						
	Director: CUSHING,	M.D., MELISSA	Address:	525 East 68th Street	New York NY 10065					
	Accession #: 12503140029	Specimen Type: Blood	Specimen Collected: 01/31/25 7:13 AM		Specimen Received Date: 01/31/25 3:13 PM					
	Last Resulted: 01/31/25 5:00 PM	5								
	≣୭୬≹ଏ	¤ , 9								

Major changes

• Phased go-live

- New assays/orderables
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

AMMONIA








LI HEPARIN (LiHep)

BNP \rightarrow NT-proBNP: specimen type


Do not correlate!



Roche Hs-Troponin T



CMP, hepatic panel, Magnesium and phosphorus in DHK



Major changes

• Phased go-live

- New assays/orderables
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

Unite changes: enterprise standardization

- CRP (Inflammation): mg/dL→ mg/L
- CRP (Cardiac): no change as mg/L
- Insulin: mIU/L \rightarrow uIU/mL
- T3: ng/mL→ ng/dL
- TSH: uIU/mL \rightarrow mIU/L
- Urine Albumin/Creatinine Ratio: $mg/g \rightarrow ug/mg$
- Urine Albumin: $mg/L \rightarrow mg/dL$
- Urine Creatinine timed: g/24h→mg/24h
- Urine Glucose timed : $g/24h \rightarrow mg/24h$
- Urine Phosphorus timed : $g/24h \rightarrow mg/24h$
- Urine Protein timed : $g/24h \rightarrow mg/24h$

Example: U ALB/U CRE Ratio

	() ALBUMIN URINE AND U ALB/U CRE RA	τιο	Status: Final result Connect: R	eleased on 2/11/2025 8:23 PM								
	Important Suggestion											
Current an	O Newer results are available. Click to view them no	ow.										
Current on	Valu	-	Range									
Siemens	Urine Creatinine 52.6 Comments:	1	mg/dL									
	No reference range is established for this test.											
	U Albumin Random 111. Comments:	9	mg/L									
	No reference range is established for the											
		.7 (H)	0.0 - 29.9 mg/gm Cr									
	Comments:											
	Albumin/Creatinine Ratio is used to clas											
	(30-300 mg malb/gm Cre), or having clinical Albuminuria (>300 mg malb/gm cre). The classification of a patient should be based upon at least 2 of 3 abnormal results on specimens collected within a 3 to 6 month time frame.											
	Should be based upon ab least 2 bi o abi	iormar resures on specim	mai results on specimens collected within a 3 to 6 month time liane									
	Performing Lab: NYP_Cornell	CLIA: 33D	0653378									
	Director: CUSHING, M.D., MELISSA	Address:	525 East 68th Street New York N	NY 10065								
	Accession #: 12504004704 Specimen Type: Urine	Specimen Collected: 02/09/25 11:35 AM		Specimen Received Date: 02/11/25 7:56 PM								
	Last Resulted: 02/11/25 8:23 PM											
	田 ê 각 호 비 덕 9											

New on Roche

	Value		Range	
Urine Creatinine Comments:	12.2		mg/dL	
lst morning urine Females 29-226 mg/dL				
Males 40-278 mg/dL				
U Albumin Random Comments:	77.1		mg/dL	
No established reference	range. The res	ults should be integra	ted into clinical	context for interpretation.
ALB/Cre Ratio	6,31	9.7 (H)	<=19.9 ug	/mg
Comments:				
comments.				
0 - 3 years: No establish	ed Reference R	ange		
	ed Reference R	Lange CLIA: 33D	00653378	
0 - 3 years: No establish		CLIA: 33E	00653378 525 East 68th Street N	New York NY 10065
0 - 3 years: No establis Performing Lab: NYP_Cornell Director: CUSHING, M.D.,MELISS/	Ą	CLIA: 33E		New York NY 10065 Specimen Received Date:
0 - 3 years: No establish Performing Lab: NYP_Cornell Director: CUSHING, M.D.,MELISS/	Ą	CLIA: 33E Address:		
0 - 3 years: No establish Performing Lab: NYP_Cornell	Ą	CLIA: 33E Address: Specimen Collected:		Specimen Received Date:

Reference ranges will change

• Particularly important for immunoassays (e.g., hormones, tumor markers)

• Pediatric reference ranges are added to certain tests

Gender specific reference ranges are added to certain tests

Example: Cortisol

Old: Siemens (higher)

Reference Ranges:

New: Roche (Lower)

Reference Ranges:

- AM 5.27 ug/dL 22.45 ug/dL AM 4.8 ug/dL 19.5 ug/dL
- PM 3.44 ug/dL 16.76 ug/dL PM 2.5 ug/dL 11.9 ug/dL

LDL calculation change from Friedewald to Martin-Hopkins

Current LDL calculation formula (Friedewald)

• LDL Calculated = Chol - (Trig/5) – HDL

New LDL Calculation (Martin-Hopkins)

- **LDL Calculated** = Non-HDL (Trig/NF*)
- **Non-HDL** = Total Cholesterol HDL Cholesterol

*Novel Factor (NF) based on Triglycerides and Non-HDL Cholesterol

The Novel Factor improves accuracy of LDL Cholesterol determination throughout a wide range of triglyceride levels.

https://www.merckmanuals.com/professional/multimedia/clinicalcalculator/martin-equation-for-low-density-lipoprotein-ldl-c

EPIC View of **Current** Lipid Profile

LIPID PROFILE		Status: Final result Connect: Released on 1/11/2025 7:32 Pl
	Value	Range
Cholesterol Total	75.0	<=199.0 mg/dL
Comments:		
Desirable:	<200 mg/dL	
Borderline High:		
High:	≻=240 mg/dL	
Triglyceride Comments:	109	<=149 mg/dL
	150 mg/dL	
Borderline High: 15		
_	0-499 mg/dL	
Very High: >	=500 mg/dL	
HDL Cholesterol	20 (L)	>=40 mg/dL
Comments:		
Low HDL Cholestero	1 (Major Risk Fact	or): < 40 mg/dL
	· · ·	• • • • • • • • • • • • • • • • • • •
High HDL Cholesterd	ol (Negative Risk F	'actor): >= 60 mg/dL
High HDL Cholestero	ol (Negative Risk F 33	'actor): >= 60 mg/dL <=99 mg/dL
-	-	
LDL Cholesterol	-	
LDL Cholesterol Comments:	33	
LDL Cholesterol Comments: Desirable:	33 < 100 mg/dL 100-129 mg/dL	
LDL Cholesterol Comments: Desirable: Above Optimal:	33 < 100 mg/dL 100-129 mg/dL	
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk: Very High Risk:	33 < 100 mg/dL 100-129 mg/dL k: 130-159 mg/dL	
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk:	33 < 100 mg/dL 100-129 mg/dL k: 130-159 mg/dL 160-189 mg/dL	
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk: Very High Risk:	33 < 100 mg/dL 100-129 mg/dL 160-189 mg/dL >= 190 mg/dL 3.8	
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk: Very High Risk: Chol HDL Ratio	33 < 100 mg/dL 100-129 mg/dL 160-189 mg/dL >= 190 mg/dL 3.8 nell	<=99 mg/dL
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk: Very High Risk: Chol HDL Ratio Performing Lab: NYP_Cor Director: CUSHING, M.D.,	33 < 100 mg/dL 100-129 mg/dL 160-189 mg/dL ≥ 190 mg/dL 3.8 nell MELISSA imen Type: Blood Specir	<=99 mg/dL CLIA: 33D0653378 Address: 525 East 68th Street New York NY 10065
LDL Cholesterol Comments: Desirable: Above Optimal: Borderline High Ris High Risk: Very High Risk: Chol HDL Ratio Performing Lab: NYP_Cor Director: CUSHING, M.D., Accession #: Spec	33 < 100 mg/dL 100-129 mg/dL 160-189 mg/dL ≥ 190 mg/dL 3.8 nell MELISSA imen Type: Blood Specir	<=99 mg/dL CLIA: 33D0653378 Address: 525 East 68th Street New York NY 10065 men Collected: Specimen Received /25 12:37 PM Date: 01/11/25 5:25

EPIC View of New Lipid Profile

UIPID PROFIL	E		Status: Final re	sult Connect: Pt Inactive
O Newer results	are available, Click to vie	w them now.		
	Value	_	Range	
Cholesterol Total	201 (H)	<=199 mg/dl	
Comments:				
-	ice of total choles	-	ne value of indiv	idual components
	LDL, non-HDL, and		<=149 mg/dl	
Triglyceride Comments:	180 (<= 149 mg/dt	
< 150 mg/dL No	vrmal fasting			
	ormal non-fasting			
-	Severely elevated			
HDL Cholesterol	30 (L)		>=40 mg/dL	
Comments:				
< 40 mg/dL Low	,			
≻= 60 mg/dL De				
LDL Cholesterol	139		mg/dL	
Comments:				
-	Primary prevention) Secondary prevention	-)		
	econdary prevention.	••)		
therapy with h	-			end lipid lowering y if cardiovascular
>= 190 mg/dL,	Severely elevated;	consider possibil:	ity of familial	
hypercholester	olemia. Lipid lowe:	ring therapy strong	gly encouraged	
Chol HDL Ratio	<mark>6.7 (</mark> F	1)	0.0 - 4.9	
-		n)		
<= 59 mg/dL (2				
	YP Cornell	CLIA: 33D	0653378	
Performing Lab: N Director: CUSHING	-		0653378 525 East 68th Street	New York NY 10065
Performing Lab: N	-	Address:		New York NY 10065 Specimen Received Date: 02/03/25 11:28 AM

Major changes

• Phased go-live

- New assays/orderables:
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

Discontinued tests

Tests:

- Caffeine,
- NAPA and Procainamide,
- CKMB,
- T3 Uptake and free Thyroxin index
- BNP,
- cTnl,

Calculations:

- Urea clearance calculation (BUN and Urine Urea Nitrogen are still offered),
- Amylase/Creatinine Ratio,

Panels/profiles:

- FSH timed stimulation profile,
- LH timed stimulation profile,
- Thyroid panel (TSH, T4, T3 Uptake and FTI)*

*Keeping Thyroid profile (TSH and fT4)

Body fluid testing

Temporary send out pending NYS approval Estimated TAT: 1-3 days

Body fluid type examples: Peritoneal, pleural, pericardial, drainage, amniotic, abscess, gastric, pancreatic, pelvic, and synovial fluids.

The below tests are still offered in house:

CSF: lactate, glucose, protein

Body fluid cell counts

Urine (phase 2): Amylase, BUN, Calcium, CL, Creatinine, glucose, Mg, PO4, K, Na, total protein, uric acid.

Major changes

• Phased go-live

- New assays/orderables:
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

Body fluid testing

Temporary send out pending NYS approval Estimated TAT: 1-3 days

Body fluid type examples: Peritoneal, pleural, pericardial, drainage, amniotic, abscess, gastric, pancreatic, pelvic, and synovial fluids.

The below tests are still offered in house:

CSF: lactate, glucose, protein


Body fluid cell counts

Urine (phase 2): Amylase, BUN, Calcium, CL, Creatinine, glucose, Mg, PO4, K, Na, total protein, uric acid.

We have high hemolysis rates

	Hemolysis Grade - % of Location draws								
Location	0	1	2	3	4				
GBG5SMICU	86%	10%	1%	2%	0%				
ACH14LBRNDLVRY	75%	19%	3%	2%	1%				
ACH15NICU	33%	52%	9%	4%	2%				
ACH 16 POSTPARTUM	92%	8%	0%	0%	0%				
GBGADLTEMRGNCY	75%	17%	4%	2%	1%				
GBGPEDSEMRGNCY	76%	17%	3%	2%	2%				
Examples of tests impacted by	LDH	К	GGT	PHOS	ТР				
hemolysis on Roche at	AST	IGE	ETOH	RF	CORT				
different hemolysis level	DBIL	ALT	ALP						
		AMM	FE						
		СК							


Semi-quantitative determination of hemolysis



Concentration

(mg/dL) (The current Siemens method does not report hemoglobin concentrations.)

Current sample Reporting- hemolysis



What will be improved for hemolysis reporting?

- Semi-quantitative to quantitative detection of hemolysis.
- Siemens: H index measured as 0, 1, 2, 3, 4
- Roche: H index measured as hemoglobin concentration (mg/dL)
- More granular assessment for each assay .
- More flexible and more customizable.
- The hemolyzed results will be reported based individual tests but not entire specimen.
- An automated detection and reporting system

Impact of hemolysis on test accuracy (examples of sensitive tests)

																					I
Analyte	Hindex (mg/dL)	0	10	15	20	25	40	60	90	100	130	175	260	350	450	530	600	700	800	900	Criteria
LDH	POOL1	235	244	250	251.5	256.5	269.5		311		367	413	500.5	588	677	765	848.5	970.5	1099	1144	Extended based on 15%
(U/L)	POOL2	673.5	675	678	682	684	700.5		752.5	760.5	797	836.5	925.5	1023	1116	1211	1301	1406	1503	1646	TAE
K (mM)	POOL1	4.3	4.3	4.4	4.4	4.4	4.4		4.6	4.6	4.7	4.8	5	5.2	5.5	5.7	5.8	6.1	6.3	6.5	Extended based on
	POOL2	4.9	5	5	5	5	5.1		5.2	5.2	5.3	5.4	5.6	5.9	6.1	6.4	6.6	6.8	7.1	7.2	0.3mM TAE
AST (U/L)	POOL1	48	49	50		50	52		56	57	60	65	73	79	88	96	103	114	132	148	Extended based on 15%
(0/L)	POOL2	426	429	428		428	432		434	435	438	443	450	457	464	471	478	488	497	501	TAE
ALT (U/L)	POOL1	44	44	44		44	44		43	45	46	47	49	50	52	54	56	59	71	75	Extended based on 15%
(0/2)	POOL2	167	165	164		164	165		165	166	166	168	171	171	172	175	178	180	184	190	TAE
DBIL (mg/dL)	POOL1	0.6	0.6	0.5		0.5	0.5	0.4	0.3		0.2	0.1	0.1	0.1	0	0	0	0	0	0	Extended based on 20%
(mg/uc)	POOL2	2.6	2.5	2.5		2.4	2.3	2.1	1.8		1.5	1.3	1	0.9	0.8	0.7	0.6	0.6	0.6	0.5	TAE
UIBC (µg/dL)	POOL1	160.5	162	164		166.5	170.5		183.5	186.6	193	206	232	257	282.5	311	337.5	366.5	418.5	427	Extended based on 20%
(µg/ut)	POOL2	136.5	140.5	141		141	146		159.5	163.8	174.5	188	215	239.5	268	295	323.5	352	390	411	TAE
HAPT	POOL1	166	165	167		166	166		166		158	152	151	153	152	152	149	151	148	148	10%
(mg/dL)	POOL2	165	168	166		167	171		165		155	153	151	153	152	151	150	148	150	148	
Folate (ng/mL)	POOL1	12.4	12.95	12.5		12.65	12.85		13.25	13.99	14.6	15.2	17	18.15	19.45	20	20	20	20	20	1ng/ml
(1.8/11.2)	POOL2	12	11.95	11.6		11.6	12.65		12.9	13.31	14	15.05	16.15	17.6	19.05	20	20	20	20	20	
Insulin	POOL1	17.4	17	16.9		16.7	16.5		16.2	14.8	13.6	12.5	12.1	10.2	7.8	6.6	8.4	5.1	4.6	3.6	12%
(mU/L)	POOL2	8	8.1	8		7.7	7.8		7		6.4	5.7	4.5	3.7	3.1	2.5	2.1	1.8	1.1	0.8	

Increasing hemolysis

RED: FDA approved H index cutoffs

Green: Extended H index ranges at NYP/Cornell for the sensitive tests

Example: LDH

• H Index- 0 - 14 mg/dL = result shown

 H Index- 15 – 40 mg/dL = See comment ; (comment – Test name (LDH) = result. This result is inaccurate due to hemolysis and may be falsely increased. Testing of a new sample is strongly advised.)

• H Index- > 40 mg/dL = See comment ;(comment – Test name (LDH) = no result reported. This test is affected by hemolysis. Testing of a new sample is strongly advised)

Example: K

• H Index- 0 - 19 mg/dL = result shown

• H Index- 20 – 100 mg/dL = See comment ;(comment – Test name (K) = result. This result is inaccurate due to hemolysis and may be falsely increased. Testing of a new sample is strongly advised.)

If the K result is critical: =Hemolyzed, Critical; (comment as above)

Note: CV K Value will post in comment box. Follow protocol to report CV, and document CV call in comment box.

 H Index- > 100 mg/dL = See comment ;(comment – Test name (K) = no result reported. This test is affected by hemolysis. Testing of a new sample is strongly advised)

Example: DBIL

- H Index- 0 24 mg/dL = result shown
- H Index- 25 60 mg/dL = See comment ;(comment Test name (DBIL) = result. This result is inaccurate due to hemolysis and may be falsely decreased. Testing of a new sample is strongly advised.)
- H Index- > 60 mg/dL = See comment ;(comment Test name (DBIL) = no result reported. This test is affected by hemolysis. Testing of a new sample is strongly advised)

Hemolysis interference is method dependent

Example: Direct bilirubin

Direct bilirubin

Direct bilirubin (neonatal)

Interference on Roche at H index of 25 mg/dL NO Interference up to H index of 600 mg/dL

Note: Neonatal bilirubin (Total and Direct) is performed on another non-Roche analyzer, which is not affected by the coming changes.

Major changes

• Phased go-live

- New assays/orderables:
- Hs-cTnl to hs-cTnT
- BNP to NT-proBNP
- Three additional tests in the Drug of Abuse (DAU) panel
- ✤ Iron & TIBC → Iron & TIBC with Transferrin Saturation

Collection procedures

- Ammonia, hsTnT and NT-proBNP: tube type change
- ♦ DHK: Serum RST tube → SST tube (phase 1) and Li-Heparin PST tubes (phase 4)
- Reference range, unit and calculation changes
- Discontinued/sendout
- Discontinued tests
- Temporary send out
- Hemolysis reporting

Contact information

Medical directors:

- Dr. Zhen Zhao: <u>zhz9010@med.cornell.edu</u>
- Dr. Sarina Yang: <u>hey9012@med.cornell.edu</u>

Operation manager:

Amanda Murphy: <u>krb9081@nyp.org</u>